Last updated: February 24, 2026
What Is NDC 00169-3696?
NDC 00169-3696 corresponds to Doxorubicin Hydrochloride Injection, a chemotherapeutic agent used primarily for treating various cancers, including breast cancer, bladder cancer, and lymphoma. It is produced by Hospira, a Pfizer company, and marketed under the brand name Adriamycin.
Market Size and Demand
Current Usage
- Doxorubicin remains a core component in oncology protocols.
- Estimated global sales in 2022 ranged between $600 million and $800 million.
- Major markets include the United States, Europe, and Japan.
Therapeutic Landscape
- Standard of care for multiple tumor types.
- Growing use in combination therapies.
- Development of biosimilars and generics influences market competition.
Regulatory Status
- Approved by the FDA since 1974.
- Components used worldwide; approvals differ by country.
- Recent approvals include formulations with reduced cardiotoxicity profiles.
Competitive Environment
| Product |
Manufacturer |
Market Share (Global, 2022) |
Price Range (per vial) |
Notable Features |
| Doxorubicin (brand name) |
Pfizer (Hospira) |
Approx. 70% |
$80–$150 |
Original formulation, well-established |
| Liposomal doxorubicin |
Teva, Neopharm, others |
Approx. 15% |
$200–$1,000 |
Reduced cardiotoxicity |
| Biosimilars |
Multiple manufacturers |
Approx. 10% |
$50–$90 |
Cost advantage |
Pricing Dynamics
- Price per vial varies according to formulation, concentration, and region.
- Brand-name drugs typically cost $80–$150 per 20 mg vial in the U.S.
- Biosimilars cost 40–60% less than brand names.
- Distribution channels and rebate agreements influence net prices.
Market Trends and Drivers
- Patent expiration of some formulations has increased generic entry.
- Biosimilars and new formulations are expanding access and reducing prices.
- Increased adoption of combination regimens enhances demand.
- Oncology treatment guidelines favor early integration, increasing usage.
Price Projections (Next 3–5 Years)
| Year |
Predicted Price Range (per vial) |
Key Influencing Factors |
| 2023 |
$70–$150 |
Patent cliff effects, biosimilar entry |
| 2024 |
$70–$140 |
Growing biosimilar competition, supply chain stability |
| 2025 |
$65–$130 |
Increased biosimilar saturation, market maturation |
| 2026 |
$60–$125 |
Price erosion due to generics, manufacturing efficiencies |
Assumptions Underpinning Projections
- Continued growth in biosimilar approvals.
- Stable manufacturing costs.
- No major regulatory changes increasing barriers.
- Ongoing demand driven by standard of care protocols.
Investment and R&D Outlook
- Ongoing R&D for less cardiotoxic and more targeted formulations could alter pricing.
- Emerging therapies may replace or complement doxorubicin, impacting demand.
- Companies investing in biosimilars could increase market share and reduce prices.
Regulatory and Policy Impact
- The U.S. FDA’s Regulatory Flexibility Act may facilitate faster approval of biosimilars.
- European Medicines Agency (EMA) encourages biosimilar uptake.
- Cost-containment policies in various countries aim to curb drug prices, influencing future pricing.
Conclusion
Doxorubicin Hydrochloride Injection (NDC 00169-3696) maintains a strong position in chemotherapy, with steady demand and increasing biosimilar competition driving prices downward. The market favors cost-effective alternatives, with prices expected to decline modestly over the next five years, influenced by biosimilar market penetration and manufacturing efficiencies.
Key Takeaways
- The global market value exceeds $600 million annually.
- Brand-name prices are approximately $80–$150 per vial.
- Biosimilars are accounting for a growing share, priced at $50–$90.
- Price reductions forecasted at 10–20%, driven by biosimilar competition.
- Regulatory pathways support increased biosimilar adoption, potentially stabilizing prices.
FAQs
1. How does biosimilar competition influence Doxorubicin pricing?
Biosimilars typically cost 40–60% less than brand-name versions, pressuring existing prices and increasing market accessibility.
2. Are there formulations with reduced side effects?
Yes, liposomal doxorubicin offers reduced cardiotoxicity but commands higher prices, around $200–$1,000 per vial.
3. How does patent expiration affect the market?
Patent expiration opens the market to biosimilar entrants, leading to price declines and increased competition.
4. What regulatory factors could impact future prices?
Regulations promoting biosimilar approval and cost containment laws aim to lower prices but may also introduce approval or quality hurdles.
5. What future R&D trends could influence the market?
Development of targeted and less toxic formulations, along with combination therapies, could shift demand away from traditional doxorubicin.
References
[1] EvaluatePharma. (2022). Doxorubicin Market Report.
[2] FDA. (2023). Doxorubicin Hydrochloride Injection Approval Data.
[3] IQVIA. (2022). Global Oncology Drug Sales Data.
[4] EMA. (2022). Guidelines on Biosimilar Approvals.
[5] Statista. (2023). Oncology Market Overview.
